PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Prostate cancer clinical stage at diagnosis
Article published in Urologia Polska 2006/59/4.

authors

Jakub Dobruch 1, Elza Modzelewska 1, Monika Popiel 1, Stanisław Szempliński 1, Gerard Grotthuss 1, Tomasz Dzik 1, Artur A. Antoniewicz 1, Piotr Chłosta 2, Andrzej Borówka 1
1 Klinika Urologii Centrum Medycznego Kształcenia Podyplomowego, I Zespół Dydaktyki Urologicznej - Oddział Urologii Międzyleskiego Szpitala Specjalistycznego w Warszawie
2 Dział Urologii Świętokrzyskiego Centrum Onkologii w Kielcach

keywords

prostate, prostate cancer, diagnosis, clinical stage

summary

Introduction. The clinical stage of the advance of prostate cancer is established on the basis of digital rectal examination (DRE) and of transrectal ultrasound (TRUS) and biopsy results.
Objective. The aim of the present study is to evaluate the stage of prostate cancer on the basis of the analysis of charts of men who underwent prostate biopsy in our department.
Material and methods. Data of men who were subjected to prostate biopsy from 1st January 2000 to 15th March 2005 because of increased sPSA (ł 4.0 ng/ml) and/or abnormal DRE and/or abnormal TRUS were analyzed.
Results. Prostate biopsy was performed on 854 men aged between 34 and 90 years (mean age - 69,15). PCa was found in 497 (58.2%) men. Clinically organ-confined prostate cancer (cT Ł2) was diagnosed in 343 (69%) of them. Among clinically organ-confined prostate cancers, well differentiated (Gl. s. Ł6) tumors were the most prevalent (82.8% of all organ confined tumors). PCa was confined to the prostate in all men aged from 40 to 49 years and in 53.2% of men aged from 70 to 79 years. Mean sPSA in men diagnosed with PCa at stages T1c, cT2a, cT2b and cT3 was 22.3 ng/ml, 17.5 ng/ml, 30.1 ng/ml and 47 mg/ml respectively.
Conclusions. Clinically organ-confined prostate cancer was diagnosed in more than 2/3 of patients with PCa. The risk of locally advanced prostate cancer increases with the age and PSA of patients. In comparison to locally advanced PCa, differentiation of clinically organ-confined prostate cancer is on the whole better.

references

  1. U. S. Cancer Statistics Working Group: United States Cancer Statistics: 2002 Incidence and Mortality. Atlanta: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2005.
  2. Jemal A, Thomas A, Murray T et al: Cancer statistics 2002. CA Cancer J Clin 2002, 52, 23-47.
  3. Paquette EL, Sun L, Paquette LR et al: Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002, 60, 756-759.
  4. Borówka A, Siedlecki P, Demkow T i in: Rak gruczołu krokowego. W książce "Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych u dorosłych" pod red. M Krzakowskiego. Warszawa, Polska Unia Onkologii, 2004: 248-268.
  5. Chan JM, Jou RM, Carroll PR: The relative impact and future burden of prostate cancer in the United States. J Urol 2004, 172, S13-S16.
  6. Wojciechowska U, Didkowska J, Tarkowski W, Zatoński W: Nowotwory złośliwe w Polsce w 2003 roku. Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie. Warszawa 2005.
  7. Dobruch J, Borówka A, Antoniewicz AA, Chłosta P: Epidemiologia raka gruczołu krokowego: zmiany obserwowane w Polsce w latach 1991-2000. Urol Pol 2005, 1, 26-30.
  8. Flemming ID, Cooper JS, Hemson DE et al: American Joint Committee on Cancer Staging Manual, 5th ed. Philadelphia, JP Lippincott 1997, 219-222.
  9. Labrie F, Dupont A, Suburu R et al: Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992, 147, 846-851.
  10. Hammerer P, Huland H: Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol 1994, 151, 99-102.
  11. Siu W, Dunn RL, Shah RB, Wei JT: Use of extended pattern technique for initial prostate biopsy. J Urol 2005, 174, 505-509.
  12. Finne P, Auvinen A, Aro J et al: Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol 2002, 41, 619-626.
  13. Gołąb A, Słojewski M, Gliniewicz B: Wpływ wyniku badania palcem przez odbytnicę, stężenia PSA w surowicy i ultrasonografii przezodbytniczej na wynik biopsji stercza (doświadczenia własne). Przeg Urol 2002, 3, 34-38.
  14. Postma R, Leenders GJLH, Roobol MJ et al: Tumor features in the control and screening arm of a randomized trial of prostate cancer. Eur Urol 2006 (w druku).
  15. Rietbergen JB, Hoedemaeker RF, Boeken Kruger AE: The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancer in a population based screening study. J Urol 1999, 161, 1192-1198.
  16. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993, 25, 270, 948-954.
  17. Partin AW, Yoo J, Carter HB et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150, 110-114.
  18. Aus G, Abbou A, Heidenreich A et al: EAU Guidelines on Prostate Cancer - Zasady postępowania u chorych na raka gruczołu krokowego. Warszawa, Biuro Wydawnicze PTU, 2004, 22-30.
  19. Farkas A, Schneider D, Perrotti M et al: National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998, 52, 444-448.
  20. Stamey TA, Donaldson AN, Yemoto CE et al: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 1998, 160, 2412-2417.
  21. Crawford ED, DeAntoni EP, Etzioni R et al: Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996, 47, 863-869.
  22. Smith DS, Catalona WJ: The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994, 152, 1732-1736.
  23. Smith DS, Humphrey PA, Catalona WJ: The early detection of prostate carcinoma with prostate-specific antigen. Cancer 1997, 80, 1852-1856.
  24. Labrie F, Candas B, Cusan N et al: Diagnosis of advanced noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996, 47, 212-217.
  25. Bartsch G, Horninger W, Klocker H et al: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the federal state of Tyrol, Austria. Urology 2001, 58, 417-424.
  26. Perrotti M, Rabbani F, Farkas A et al: Trends in poorly differentiated prostate cancer 1973-1994; observations from the Surveillance, Epidemiology and End Results Database. J Urol 1998, 160, 811-815.
  27. Newcomer LM, Stanford JL, Blumenstein BA, Brawer MK: Temporal trends in rates of prostate cancer: Declining incidence of advanced stage disease, 1974 to 1994. J Urol 1997, 158, 1427-1430.
  28. Dobruch J, Borówka A, Antoniewicz AA, Chłosta P: Screening study aiming at an early diagnosis of the prostatic cancer: related epidemiological problems and natural history of the disease. Urol Pol 2004, 3, 12-22.

correspondence

Jakub Dobruch
Oddział Urologii Międzyleskiego Szpitala Specjalistycznego
ul. Bursztynowa 2
04-749 Warszawa
tel. 0 503 072 230
kubadobr@wp.pl